Vogelman B, Gundmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–47 ArticlePubMedCAS Google Scholar
Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74 Suppl.: 63–70 Google Scholar
White CA, Toothaker RD, Smith AL, et al. In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli. Antimicrob Agents Chemother 1989; 33: 1046–51 ArticlePubMedCAS Google Scholar
Onyeji CO, Nicolau DP, Nightingale CH, et al. Optimal times above MICs of ceftibuten and cefaclor in experimental intraabdominal infections. Antimicrob Agents Chemother 1994; 38: 1112–7 ArticlePubMedCAS Google Scholar
Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992; 36: 552–7 ArticlePubMedCAS Google Scholar
Kalman D, Barriere SL, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother 1992; 36: 453–7 ArticlePubMedCAS Google Scholar
Blouin RA, Kneer J, Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother 1989; 33: 291–6 ArticlePubMedCAS Google Scholar
Hayton WL, Kneer J, Blouin RA, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis. Antimicrob Agents Chemother 1990; 43: 1318–21 Article Google Scholar
Koup JR, Dubach UC, Brandt R, et al. Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother 1988; 32: 573–9 ArticlePubMedCAS Google Scholar
Tam YK, Kneer J, Dubach UC, et al. Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother 1989; 33: 957–9 ArticlePubMedCAS Google Scholar
Brittain DC, Scully BE, Hirose T, et al. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther 1985; 38: 590–4 ArticlePubMedCAS Google Scholar
Faulkner RD, Fernandez P, Lawrence G, et al. Absolute bioavailability of cefixime in man. J Clin Pharmacol 1988; 28: 700–6 PubMedCAS Google Scholar
Guay DRP, Meatherall RC, Harding GK, et al. Pharmacokinetics of cefixime (CL 284, 635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 1986; 30: 485–90 ArticlePubMedCAS Google Scholar
Brisson AM, Bryskier A, Millerioux L, et al. Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults. Antimicrob Agents Chemother 1984; 26: 513–8 ArticlePubMedCAS Google Scholar
Daschner FD, Hemmer KA, Offermann P, et al. Pharmacokinetics of cefotiam in normal humans. Antimicrob Agents Chemother 1982; 22: 958–60 ArticlePubMedCAS Google Scholar
Rouan MC, Lecaillion JB, Guibert J, et al. Pharmacokinetics of cefotiam in humans. Antimicrob Agents Chemother 1985; 27: 177–80 ArticlePubMedCAS Google Scholar
Korting HC, Schäfer-Korting M, Kees F, et al. Skin tissue fluid levels of cefotiam in healthy man following oral cefotiam hexetil. Eur J Clin Pharmacol 1990; 39: 33–6 ArticlePubMedCAS Google Scholar
Maaß L, Malerczyk V, Verho M. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers. Infection 1987; 15: 207–10 ArticlePubMed Google Scholar
Nakayama I, Akieda Y, Yamaji E, et al. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR 810) to healthy volunteers. J Clin Pharmacol 1992; 32: 256–66 PubMedCAS Google Scholar
Paradis D, Vallée F, Allard S, et al. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 2085–92 ArticlePubMedCAS Google Scholar
Borin MT, Hughes GS, Spillers CR, et al. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrob Agents Chemother 1990; 34: 1094–9 ArticlePubMedCAS Google Scholar
O’Neill P, Nye K, Douce G, et al. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrob Agents Chemother 1990; 34: 232–4 ArticlePubMed Google Scholar
Tremblay D, Dupront A, Ho C, et al. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother 1990; 26 Suppl. E: 21–8 PubMedCAS Google Scholar
Barbhaiya RH, Shukla UA, Gleason CR, et al. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1990; 34: 1204–9 ArticlePubMedCAS Google Scholar
Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol 1992; 32: 725–31 PubMedCAS Google Scholar
Shyu WC, Wilber RB, Pittman KA, et al. Effect of antacid on the bioavailability of cefprozil. Antimicrob Agents Chemother 1992; 36: 962–5 ArticlePubMedCAS Google Scholar
Shyu WC, Wilber RB, Pittman KA, et al. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment. J Clin Pharmacol 1991; 31: 372–6 PubMedCAS Google Scholar
Barr WH, Lin C-C, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14: 93–100 ArticlePubMedCAS Google Scholar
Kelloway JS, Awni WM, Lin CC, et al. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency. Antimicrob Agents Chemother 1991; 35: 2267–74 ArticlePubMedCAS Google Scholar
Nakashima M, Uematsu T, Takiguchi T, et al. Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. J Clin Pharmacol 1988; 28: 246–52 PubMedCAS Google Scholar
Bundtzen RW, Toothaker RD, Nielson OS, et al. Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 1981; 19: 443–9 ArticlePubMedCAS Google Scholar
Colaizzi PA, Goodwin SD, Poynor WJ, et al. Single-dose pharmacokinetics of cefuroxime and cefuroxime and cefamandole in healthy subjects. Clin Pharm 1987; 6: 894–9 PubMedCAS Google Scholar
Ginsburg CM, McCracken GH, Petruska M, et al. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985; 28: 504–7 ArticlePubMedCAS Google Scholar
Harding SM, Williams PO, Ayrton J. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 1984; 25: 78–82 ArticlePubMedCAS Google Scholar
Williams PO, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984; 13: 191–6 ArticlePubMedCAS Google Scholar
Roller S, Lode H, Stelzer I, et al. Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis 1992; 11: 851–5 ArticlePubMedCAS Google Scholar
Therasse DG, Farlow DS, Davidson RL, et al. Effects of renal dysfunction on the pharmacokinetics of loracarbef. Clin Pharmacol Ther 1993; 54: 311–6 ArticlePubMedCAS Google Scholar
Manufacturer’s data on ceftibuten (SCH 39720), 1992. Schering Corporation, Kenilworth, New Jersey 07033, USA
Muranushi N, Yoshikawa T, Yoshida M, et al. Transport characteristics of ceftibuten, a new oral cephem, in rat intestinal brush-border membrane vesicles: relationship to oligopeptide and amino β-lactam transport. Pharm Res 1989; 6: 308–12 ArticlePubMedCAS Google Scholar
Sugawara M, Iseki K, Miyazaki K, et al. Transport characteristics of ceftibuten, cefixime, and cephalexin across human jejunal brush-border membrane. J Pharm Pharmacol 1991; 43: 882–4 ArticlePubMedCAS Google Scholar
Yoshikawa T, Muranushi N, Yoshida M, et al. Transport characteristics of ceftibuten (7432-S), a new oral cephem, in rat intestinal brush-border membrane vesicles: proton-coupled and steroselective transport of ceftibuten. Pharm Res 1989; 6: 302–7 ArticlePubMedCAS Google Scholar
Faulkner RD, Bohaychuk W, Lanc RA, et al. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother 1988; 21: 787–94 ArticlePubMedCAS Google Scholar
Faulkner RD, Bohaychuk W, Desjardins RE, et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol 1987; 27: 807–12 PubMedCAS Google Scholar
Santella PJ, Rubinfeld J. Bioavailability of cefadroxil. In: Duricef® (cefadroxil monohydrate): rationale and clinical experience. Postgraduate Medicine Communications; McGraw-Hill Medical Communication Service, New York, New York: 1979 June: 20–6 Google Scholar
Richards D. Bioavailability and excretion characteristics of cefadroxil. In: Duricef® (cefadroxil monohydrate): rationale and clinical experience. Postgraduate Medicine Communications; McGraw-Hill Medical Communication Service, New York, New York: 1979 June: 27–30 Google Scholar
Wise R, Bennett SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984; 13: 603–10 ArticlePubMedCAS Google Scholar
Nakashima M, Uematsu T, Takiguchi Y, et al. Phase I study of cefixime, a new oral cephalosporin. J Clin Pharmacol 1987; 27: 425–31 PubMedCAS Google Scholar
Malerczyk V, Maa L, Verho M, et al. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative. Infection 1987; 15: 211–4 ArticlePubMedCAS Google Scholar
Backhouse C, Wade A, Williamson P, et al. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients. J Antimicrob Chemother 1990; 26 Suppl. E: 29–34 PubMed Google Scholar
Barbhaiya RH, Shukla UA, Gleason CR, et al. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother 1990; 34: 1198–203 ArticlePubMedCAS Google Scholar
Lode H, Müller C, Borner K, et al. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother 1992; 36: 144–9 ArticlePubMedCAS Google Scholar
Wise R, Nye K, O’Neill P, et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34: 1053–5 ArticlePubMedCAS Google Scholar
Sommers DK, Van Wyk M, Williams PO, et al. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984; 25: 344–7 ArticlePubMedCAS Google Scholar
Hoffstedt B, Walder M. Influence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue and fluid in humans. Antimicrob Agents Chemother 1981; 20: 783–6 ArticlePubMedCAS Google Scholar
Wise R, Donovan IA, Ambrose NS, et al. The penetration of cefoxitin into peritoneal fluid. J Antimicrob Chemother 1981; 8: 435–7 Article Google Scholar
Wise R, Gillett AP, Cadge B, et al. The influence of protein binding upon tissue fluid levels of six β-lactam compounds. J Infect Dis 1980; 142: 77–82 ArticlePubMedCAS Google Scholar
Calain P, Krause KH, Vaudaux P, et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987; 155: 187–91 ArticlePubMedCAS Google Scholar
Chambers HF, Mills J, Drake TA, et al. Failure of a once-daily regimen of cefonicid for the treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis 1984; 6 Suppl. 4: S870–4 ArticlePubMed Google Scholar
Tompsett R, Shultz S, McDermott W. The relation of protein binding to the pharmacology and antibacterial activity of penicillins X, G, dihydro F, and K. J Bacteriol 1947; 53: 581–95 PubMedCAS Google Scholar
Nye KJ, Shi YG, Andrews JM, et al. Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother 1989; 24: 23–8 ArticlePubMedCAS Google Scholar
Stone JW, Linong G, Andrews JM, et al. cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother 1989; 23: 221–8 ArticlePubMedCAS Google Scholar
Kavi J, Andrews JM, Ashby JP, et al. Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother 1988; 22: 911–6 ArticlePubMedCAS Google Scholar
Nye K, O’Neill P, Andrews JM, et al. Pharmacokinetics and tissue penetration of cefprozil. J Antimicrob Chemother 1990; 25: 831–5 ArticlePubMedCAS Google Scholar
LePage MC, Trottier S, Bergeron MG, et al. Pharmacokinetics and blister fluid penetration of loracarbef after single and multiple doses [abstract 1167]. Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1990 Oct 21–24: Atlanta. American Society for Microbiology: Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990
Okamoto MP, Chin A, Gill MA, et al. Analysis of cefepime tissue penetration into human appendix. Pharmacotherapy 1991; 11: 353–8 PubMedCAS Google Scholar
Chadha D, Wise R, Baldwin DR, et al. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. J Antimicrob Chemother 1990; 25: 959–63 ArticlePubMedCAS Google Scholar
Arkell D, Ashrap M, Andrews JM, et al. An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy [letter]. J Antimicrob Chemother 1992; 29: 473–4 ArticlePubMedCAS Google Scholar
Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in human subjects. Drug Invest 1991; 3: 291–8 Google Scholar
Baldwin DR, Andrews JM, Ashby JP, et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401–2 ArticlePubMedCAS Google Scholar
Saxby MF, Arkell DG, Andrews JM, et al. Penetration of cefpirome into prostatic tissue [letter]. J Antimicrob Chemother 1990; 25: 488–90 ArticlePubMedCAS Google Scholar
Baldwin DR, Maxwell SRJ, Honeybourne D, et al. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 1991; 28: 79–86 ArticlePubMedCAS Google Scholar
Muller-Serieys C, Bancal C, Dombret MC, et al. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother 1992; 36: 2099–103 ArticlePubMedCAS Google Scholar
Baldwin DR, Wise R, Andrews JM, et al. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. J Antimicrob Chemother 1992; 30: 67–71 ArticlePubMedCAS Google Scholar
Gehanno P, Andrews JM, Ichou F, et al. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother 1990; 26 Suppl. E: 47–51 PubMed Google Scholar
Couraud L, Andrews JM, Lecoeur H, et al. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother 1990; 26 Suppl. E: 35–40 PubMed Google Scholar
Naber KG, Kinzig M, Adam D, et al. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 1991; 19: 30–5 ArticlePubMedCAS Google Scholar
Cho N, Fukunaga K, Kunii K, et al. Basic and clinical studies on CS-807 in the obstetric and gynecological field. Chemotherapy 1988; 36 Suppl. 1: 923–40 Google Scholar
Shyu WC, Reilly J, Campbell DA, et al. Penetration of cefprozil into tonsillar and adenoidal tissues. Antimicrob Agents Chemother 1993; 37: 1180–3 ArticlePubMedCAS Google Scholar
Perea EJ, Ayarra J, Garcia Iglesias MC, et al. Penetration of cefuroxime and ceftazidime into human lungs. Chemotherapy 1988; 34: 1–7 ArticlePubMedCAS Google Scholar
Jetlund O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and Phenoxymethylpenicillin in patients undergoing tonsillectomy. Int J Clin Pharmacol Res 1991; 11: 1–6 PubMedCAS Google Scholar
Winter J, Dhillon P. Penetration of cefuroxime into bronchial mucosa following oral administration of cefuroxime axetil [letter]. J Antimicrob Chemother 1991; 27: 556–8 ArticlePubMedCAS Google Scholar
Stenquist M, Lindahl D, Eriksson T, et al. Penetration of loracarbef into maxillary sinus fluid and tonsillary tissue after single dose administration [abstract]. 17th International Congress of Chemotherapy; 1991 Jun 23–28, Berlin
Goto J, Ikuta M, Shigeno H, et al. Laboratory and clinical study of cefetamet pivoxil in respiratory infections. Chemotherapy 1990; 38 Suppl. 1: 185–92 Google Scholar
Tod B, Chaine G, Oliary J, et al. Penetration of cefixime in the anterior chamber of the human eye [in French]. J Fr Ophthalmol 1991; 14: 477–80 CAS Google Scholar
Cherrier P, Tod M, Le Gross V, et al. Cefotiam concentrations in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil. Eur J Clin Microbiol Infect Dis 1993; 12: 211–5 ArticlePubMedCAS Google Scholar
Taugourdeau MC, Hagege H, Laurent-Puig P, et al. Pharmacokinetics of cefpirome in patients with cirrhosis and ascites [abstract-746]. Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14: Anaheim. American Society for Microbiology: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992
Dumont R, Guetat F, Andrews JM, et al. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother 1990; 26 Suppl. E: 41–6 PubMed Google Scholar
Yura J, Shinagawa N, Mizuno A, et al. CS-807 in surgery. Chemotherapy 1988; 36 Suppl. 1: 664–76 Google Scholar
Pan HT, Kumari P, de Dilva AF, et al. Determination of ceftibuten in sputum by column-switching high-performance liquid chromatography on-line with thermospray mass spectrometry. J Pharm Sci 1993; 82: 52–5 ArticlePubMedCAS Google Scholar
Hedström SA, Lidgren L, Nilsson-Ehle I. Cefuroxime in acute septic arthritis. Scand J Infect Dis 1984; 16: 79–82 ArticlePubMed Google Scholar
Guerra R, Casu L, Giola L, et al. Penetration of parenteral cefuroxime into the human aqueous humor. Arzneimittel Forschung 1981; 31: 861–3 PubMedCAS Google Scholar
Kusmiesz H, Shelton S, Brown O, et al. Loracarbef concentrations in middle ear fluid. Antimicrob Agents Chemother 1990; 34: 2030–1 ArticlePubMedCAS Google Scholar
Nahata MC, Kohlbrenner VM, Barson WJ. Pharmacokinetics and cerebrospinal fluid concentrations of cefixime in infants and young children. Chemotherapy 1993; 39: 1–5 ArticlePubMedCAS Google Scholar
Wolff M, Chavanet P, Kazmierczak A, et al. Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. J Antimicrob Chemother 1992; 29 Suppl. A: 59–62 PubMed Google Scholar
Nix DE, Wilton JH, Velasquez N, et al. Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges. J Antimicrob Chemother 1992; 29 Suppl. A: 51–7 PubMed Google Scholar
Edwards MS, Baker CJ, Butler KM, et al. Penetration of cefuroxime into ventricular fluid in cerebrospinal fluid shunt infections. Antimicrob Agents Chemother 1989; 33: 1108–10 ArticlePubMedCAS Google Scholar
del Rio M, Chrane DF, Shelton S, et al. Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis. Antimicrob Agents Chemother 1982; 22: 990–4 Article Google Scholar
Müller C, Nutland A. The penetration of cefuroxime into the cerebrospinal fluid through inflamed and non-inflamed meninges. J Antimicrob Chemother 1980; 6: 279–83 ArticlePubMed Google Scholar
Barbhaiya RH, Knupp CA, Forgue ST, et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990; 48: 268–76 ArticlePubMedCAS Google Scholar
Kneer J, Tam YK, Blouin RA, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother 1989; 33: 1952–7 ArticlePubMedCAS Google Scholar
Lameire N, Malerczyk V, Drees B, et al. Single-dose pharmacokinetics of cefpirome in patients with renal impairment. Clin Pharmacol Ther 1992; 52: 24–30 ArticlePubMedCAS Google Scholar
Shyu WC, Pittman KA, Wilber RB, et al. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol 1991; 31: 362–71 PubMedCAS Google Scholar
Brogard JM, Arnaud JP, Blickle JF, et al. Biliary elimination of cefotiam, an experimental and clinical study. Chemotherapy 1986; 32: 222–35 ArticlePubMedCAS Google Scholar
Höffler D, Koeppe P, Corcilius M, et al. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection 1990; 18: 157–62 ArticlePubMed Google Scholar
Shyu WC, Shah VR, Campbell DA, et al. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J Clin Pharmacol 1992; 32: 798–803 PubMedCAS Google Scholar
Rowe JW, Andres A, Tobin JD, et al. Age-adjusted standard for creatinine clearance. Ann Intern Med 1976; 84: 567–9 PubMedCAS Google Scholar
Tam YK, Kneer J, Dubach UC, et al. Effects of timing of food and fluid volume on cefetamet pivoxil absorption in healthy normal volunteers. Antimicrob Agents Chemother 1990; 34: 1556–9 ArticlePubMedCAS Google Scholar
Faulkner RD, Yacobi A, Barone JS, et al. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis 1987: 6: 963–70 ArticleCAS Google Scholar
Deppermann KM, Garbe C, Hasse K, et al. Comparative pharmacokinetics of cefotiam hexetil, cefuroxime, cefixime, cephalexin, and effect of H2 blocker, standard breakfast and antacids on the bioavailability of cefotiam hexetil [abstract-1223]. Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1989 Sept 17–20: Houston. American Society for Microbiology: Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989
Barbhaiya RH, Shulka UA, Gleason CR, et al. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother 1990; 34: 1210–3 ArticlePubMedCAS Google Scholar
Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36: 796–800 ArticlePubMedCAS Google Scholar
Uchida E, Oguchi K, Hisaoka M, et al. Effects of ranitidine, metoclopramide, and anisotropine methylbromide on the availability of cefpodoxime proxetil (CS-807) in Japanese healthy subjects. Jpn J Clin Pharmacol Ther 1988; 19: 573–9 ArticleCAS Google Scholar
Quintiliani R, Nightingale CH, Freeman CD. Pharmacokinetic and pharmacodynamic selection with particular attention to oral cephalosporins. Infect Dis Clin Pract 1994; 3: 1–7 Article Google Scholar
King A, Boothman C, Phillips I. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins. Eur J Clin Microbiol Infect Dis 1990; 9: 677–85 ArticlePubMedCAS Google Scholar
Wiedemann B, Luhmer E, Zühlsdorf T. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, enterobacteriaceae and Pseudomonas aeruginosa, including β-lactamase producers. Infection 1991; 19: 363–9 ArticlePubMedCAS Google Scholar
Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor, and cefadroxil. Infection 1991; 19: 353–62 ArticlePubMedCAS Google Scholar
Ackerman BH, Ross J, Tofte RW, et al. Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother 1984; 25: 785–6 ArticlePubMedCAS Google Scholar
Jones RN, Barry AL. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S, SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother 1988; 32: 1576–82 ArticlePubMedCAS Google Scholar
Knothe H, Shah PM, Eckardt O. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Infection 1991; 19: 370–6 ArticlePubMedCAS Google Scholar